LXEO
Lexeo Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$467.49M
P/E Ratio
—
EPS
$-1.86
Beta
2.00
52W High
$10.99
52W Low
$1.90
50-Day MA
$6.61
200-Day MA
$6.88
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-63.80M |
| EBITDA | $-108.67M |
| Operating Margin | 0.00% |
| Return on Equity | -55.00% |
| Return on Assets | -32.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.38 |
| Price-to-Book | 1.72 |
| Price-to-Sales (TTM) | 478.26 |
| EV/Revenue | 416.34 |
| EV/EBITDA | -6.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $74.09M |
| Float | $47.06M |
| % Insiders | 0.84% |
| % Institutions | 113.24% |
Analyst Ratings
Consensus ($19.64 target)
2
Strong Buy9
BuyData last updated: 4/8/2026